Prodrug of LY354740, highly selective and potent agonist of group II mGlu receptors (mGluR2)

Novel inhibitor of the type I transforming growth factor beta receptor (TβRI)

Novel F1F0-ATPase modulator, significantly decreasing M2 glutamate and increasing M4 glutamate

Nove fluorescent probe for highly sensitive monitoring drug induced lysosomal pH value changes, exhibiting good biological compatibility, low cytotoxicity and high resistance to photobleaching

Natural Potent Marine-Derived Elastase Inhibitor

Inhibitor of viral replication, especially useful in the treatment of the Herpes family of viruses which includes Herpes Simplex 1 and 2 , EBV , CMV and Varicella.

Inhibitor of cyclooxygenase (COX); Pan partial agonist of PPARγ, PPARα and PPARβ/δ

Novel inhibitor of the transcriptional activity of β-catenin, degrading the expression of β-catenin by stabilizing axin 2 and diminishing downstream proteins levels, including c-Myc and cyclin D1, effectively shrinking tumor xenograft derived from colonic

TRPC4/5 channel blocker, exhibiting antidepressant and anxiolytic effects

Novel selective muscarinic M1 receptor positive allosteric modulator, significantly improved scopolamine-induced cognitive deficits without prominent signs of diarrhea at up to 1000 mg/kg in mice

Novel selective muscarinic M1 receptor positive allosteric modulator, showed both significant improvement of scopolamine-induced cognitive deficits and severe diarrhea

M4K2209 is a potent, selective BMP type I receptor ALK2 inhibitor with IC50 of 9 nM, >180-fold selective over ALK5 (IC50=2427 nM).

Novel potent and selective ALK2 inhibitor, showing high initial brain uptake, including in the region of interest (pons)

Novel CNS Penetrant ALK2 Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma

Partial antagonist of mGlu5

Novel Peptide Deformylase (PDF) Inhibitor, having inhibitory activity against HeLa, A549 and MCF-7

Novel potent and selective inhibitor of UppS without off-target effects on membrane potential

Novel inhibitor of the bacterial lipoprotein targeting chaperone, LolA

Natural immunomodulator, significantly decreasing TNF-α and IL-10 cytokine production, regulating the NF-κB and MAPK signaling pathways, displaying the strongest antiproliferative effects with IC50 values of 2.84 and 0.95 μM against A431 and HeLa cancer c

Potent and selective inhibitor of the induction of cytopathic effect by CHIKV and VEEV

Polyether ionophore antibiotic, inhibiting proliferation and induces apoptosis in myoblast cells

Novel reversible monoacylglycerol lipase (MAGL) inhibitor

Inhibitor of TNF-α, preventing and restoring memory deficits associated with neuropathic pain

Inhibitor of the amebicidal activity of activated murine macrophages, helping the parasite to survive within the mouse large intestine and increasing the survival of C. elegans exposed to H2O2

Potent CB2 receptor inverse agonist

Selective modulator of plasmodial Hsp70s with antimalarial activity

Toll-like receptor 2/6 (TLR-2/6) agonist, regulating Lcn2 gene, promoting collateral growth

TLR2/6 agonist, activating the MyD88 pathway, provoking natural killer (NK) cell activation, increasing co-stimulators CD80/86 and CD40

Novel quantitative chemical probe for live cell labeling and imaging of proteins that are sensitive to redox modifications

Natural anticancer, anti-inflammatory, neuroleptic agent, also having human acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activities

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B).

Novel potent and highly selective MAO-B Inhibitor

Potent and selective MAO-B inhibitor

Novel potent selective and competitive inhibitor of MAO-B (IC 50 : 0.69 μM)

Novel potent and competitive inhibitor of MAO-B (IC 50 : 0.51 μM), also inhibiting BChE (IC 50 : 7.00 μM)

Novel selective MAO-B inhibitor

Novel stable antibody-drug conjugate (ADC) in mouse serum

Inhibitor of neuronal norepinephrine reuptake, reducing symptoms of anxiety associated with depression.

Novel highly efficient dual type I/II FMS-like tyrosine kinase inhibitor, disrupting the growth of leukemic cells

Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5

Novel, active, and less toxic anti-tuberculosis (anti-TB) agent

Neurokinin receptor antagonist with antiemetic activity

Novel potent tyrosinase inhibitor from the Gram-negative bacterium Massilia albidiflava DSM 17472T

Novel potent inhibitor of May1 with Ki = 12 ± 1 nM, also inhibiting wild-type HIV-1 protease with Ki = 32 ± 5 pM and three drug resistance-associated mutants with Ki values ranging from 24 to 320 pM

Natural Anti-inflammation Agent, Attenuating Amyloid Plaques by Inducing Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model

Novel potent inhibitor of the membrane-bound retinoid isomerase RPE65

Prodrug of MB05032, acting as potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes

Novel Inhibitor of Mycobacterium tuberculosis α-1,4-Glucan Branching Enzyme (GlgB)

Novel inhibitor of dengue and West Nile virus NS2B-NS3 protease

Novel non-hemolytic and low toxic inhibitor of metallo-β-lactamases (MBLs), restoring the activity of meropenem against Escherichia coli, Citrobacter freundii, Proteus mirabilis and Klebsiella pneumonia, which carried resistance genes of blaNDM-1

Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM)

Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM)

Deuterium-substituted anticancer agent, plinabulin, exhibiting better pharmacokinetic characteristics than that of plinabulin

The first selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase

Potent antibacterial agent against a wide range of Gram-positive and Gram-negative bacteria

Novel antibacterial agent, remarkably potent against antibiotic-resistant bacterial strains such as MDR A. baumannii , ESBL-producing Klebsiella pneumoniae, VRE, and MRSA

Antibacterial agent, with a relatively narrow spectrum against bacteria and a very high CC 50 value

Novel specific inhibitor of HA-mediated viral entry, inhibiting HPAI H5N1 virus strain A/Hong Kong/H5N1

Topical nonnucleoside reverse transcriptase inhibitor, partially preventing vaginal RT-SHIV infection of macaques

Potent and HDAC class I-selective inhibitor

Novel potent acetylcholinesterase (AChE) inhibitor

The first inhibitor of forkhead Box Protein C2 (FOXC2)

Novel selective PARP1 inhibitor, inhibitng apoptosis and blocking poly ADP-ribosylation of histone H1 in hydrogen peroxide treated SH-SY5Y neuroblastoma cells

Novel hybrid retinoid-HDAC inhibitor

Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively)

Novel neurotropic agent

Specific and highly fluorescent substrate for caspase-1, also acting as a substrate for caspase-4

Novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1)

First-in-class inhibitor of MFS efflux pump CaMdr1p

Novel inverse agonist for the pancreatic-type ATP-sensitive K channel as vascular relaxing agent

Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE)

Albumin-binding prodrug of Doxorubicin

Novel potent F508del-CFTR corrector, modulating poly-ADP ribose polymerase 3 and poly-ADP ribose polymerase 16 activities

Selective NA reuptake inhibitor with 5-HT3 receptor antagonism

Novel inhibitor of p53-MDM2 interaction

Novel potent and selective degrader of Mcl-1

Novel reversible covalent inhibitor for Mcl-1 with improved water solubility than Mcl-1 Inhibitor-5

Novel selective Mcl-1 inhibitor

The first reversible covalent inhibitor for Mcl-1, a protein-protein interaction (PPI) target

Novel potent and selective inhibitor of the apoptosis regulating proteins Mcl-1

Novel mc (maleimidocaproyl) linker plus MMAD (Monomethylauristatin D) to be used for prepare antibodies conjugates via cysteine-capped mechanism

Novel highly selective inhibitor of monocarboxylate transporter 4 (MCT4/SLC16A3), resulting in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells

Novel SARS-CoV-2 Main Protease (Mpro) inhibitor, binding to Subsites S1 and S2 (Kd=1.3 µM)

First-in-class highly potent PROTAC degrader of MDM2

Diuretic agent, impling an increase in the Na+ excretion and showing antihypertensive effect

Novel valproic acid (VPA) derivative, as a potent STAT3 inhibitor

Novel partial PPARgamma ligand, displaying partial agonist activity in biochemical and cell-based transactivation assays, and reversed insulin resistance

Novel proteolysis-resistant self-localizing ligand (SL), sustaining PM localization of eDHFR-fusion proteins (over several hours to a day), inducing prolonged signal activation and cell differentiation

Novel MC5R antagonist

Novel potent and highly selective melanocortin-3 receptor (MC3R) agonist, showing greater than 140-fold selective for the mMC3R over the mMC4R, possessed 70 nM potency at the mMC3R, and partially stimulated the mMC4R at 100 μM concentrations without antag

Novel potent and nonselective MC3R and MC4R macrocyclic agonist. decreased food intake and respiratory exchange ratio (RER)

Novel Inhibitor of BAF, activating latent HIV-1

Novel peroxisome proliferator activated receptor

Novel peroxisome proliferator activated receptor γ (PPARγ) ligand

Dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase

Potent Peptide dual inhibitor of MDM2/X, inhibiting p53 interactions with MDM2 (IC50 = 10 nmol/L) and MDMX (IC50 = 100 nmol/L), inducing apoptosis and cell cycle arrest of cell lines with overexpressed MDM2/X

Novel potent dual MDM2/XIAP inhibitor

Novel inhibitor of the MDM2-p53 interaction

Potent ligand of the central CB1 receptor

Novel selective inhibitor of succinate dehydrogenase (complex II) of dermatophyte species

Potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs), activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD3100

Second generation papaverine analog, acting as an anticholinergic agent

Selective FXR antagonist, ameliorates glucose homeostasis in type 2 diabetic mice

Polyketide antibiotic, acting as a AKT selective kinase inhibitor, alkylating a regulatory loop cysteine

Progestational hormone, for the treatment of menstrual irregularities, prostatic hypertrophy, and endometrial carcinoma

Potent sPLA2 inhibitor, having no effect on arachidonic acid release and platelet activating factor synthesis

Inducer of Megakaryocyte Differentiation in Erythroleukemia Cells, Impairing Bcr-Abl Signaling Cascades

Natural dual inhibitor of COX-2 and EGFR, improving program death 1 (PD-1) checkpoint blockade therapy through normalizing tumor vasculature and PD-L1 downregulation

Prodrug of melarsen oxide (Mel Ox), irreversibly binding to vicinal sulfhydryl groups on pyruvate kinase, disrupting energy production in the parasite

Inhibitor of cholesterol esterification

Novel Multi-Kinase Inhibitor, Triggering Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition

Potent, selective and orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4)

5-HT2A/D2 receptor antagonist

Novel potent and selective nonpeptide kinin B2 receptor antagonist

Novel Cell Death-Inducing Kinase Inhibitor with Enhanced Selectivity for Cyclin-Dependent Kinases; Antimalarial

Potent cell-permeable, ATP site-targeting inhibitor of CDKs

Potent cell-permeable, ATP site-targeting inhibitor of CDKs

Apoptosis inducer, triggering ROS dependent autophagy-associated apoptosis in a variety of human cancer cell lines and against mutant KRAS expressing cancer cells involving AKT-dependent ROS production

LXR-α antagonist, inhibiting hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells

Anabolic and androgenic agent

Novel selective and potent full KOP receptor agonist with fewer side effects (e.g., sedation or anhedonia) than classic KOP receptor

Novel selective GPR120 agonist

Cyclooxygenase 3 (COX3) inhibitor, acting as a potent inductor of cytochrome P450 isoenzymes CYP2B6 and CYP3A4

Potent, long-lasting, and selective antagonist of morphine-mediated antinociception

Natural potent anti-proliferative agent, inducing apoptotic cell death

Inhibitor of pro-inflammatory mediator release from mast cells

Useful pharmaceutical building block

Novel photosensitizer as a photodynamic antimicrobial agent against Staphylococcus aureus, Escherichia coli, Candida albicans, and Methicillin-resistant S. aureus (MRSA)

Novel inhibitor of ABCG2 transporter function

Natural antifungal agent, significantly inducing lipid peroxidation, activating the antioxidant enzymes, and exhibiting effective activity against F. solani (EC50 = 10.56 µM)

Metablite of PRIMA-1 and APR-246, covalently binding to cysteine residues in mutant p53 and wild type p53, and being increased in unfolded p53, inducing massive apoptosis in p53 null tumor cells

Novel Class of Cannabinoid CB2 Receptor Inverse Agonist

Peripherally restricted μ-opioid antagonist

Highly Selective Class II MET Inhibitor

Dopamine D2 antagonist, antiemetic

Non-depolarizing muscle relaxant

Radiographic Contrast Agent

Novel Dual Fluorescent and Magnetic Resonance False Neurotransmitter

Novel potent negative allosteric modulator (NAM) of mGlu2

Novel potent inhibitor of the p53-MDM2 interaction with an IC50 value of 67.5 nmol/L, against acute leukemia cell lines with different p53 status and was much less effective in inducing MDM2 degradation

mG2N001 is a potent negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) with IC50 of 93 nM.

Novel, multi-targeted kinase inhibitor, demonstrating potent inhibition of Trk, RET and DDR, in addition to Met, Axl and VEGFRs

Selective metabotropic glutamate 2/3 receptor agonist

Potent and orally active group II mGluR antagonist with antidepressant-like potential

Near-infrared cyanine dye, acting as an optical imaging agent

Novel photodynamic antitumor agent

Novel tyrosinase inhibitor, showing concentration-dependent inhibitory effects with no significant cytotoxicity in cell viability assay

Novel potent HDAC inhibitor, possessing potent anticancer activities

Novel potent histone deacetylase (HDAC) inhibitor, inducing apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells

Novel topoisomerase II inhibitor, markedly inducing apoptotic cell death via the mitochondria-mediated intrinsic pathway in LNCaP cells

Novel tyrosinase inhibitor, down-regulating of MITF and tyrosinase through direct tyrosinase inhibition

Novel sensitizer of cancer cells, significantly increasing DNA damage as determined by DNA breakage, levels of damage-responsive proteins, and DNA foci

Novel inducer of G2/M phase arrest in the cell cycle progression, resulting in growth inhibition and induction of apoptosis in a concentration-dependent manner, and inhibition of proliferation in a time-dependent manner

Novel inhibitor of nitric oxide-induced melanogenesis, targeting the NO-induced cGMP signaling pathway

Novel tyrosinase inhibitor, directly inhibiting mushroom tyrosinase

Novel tyrosinase inhibitor, suppressing UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress

Novel Chemically Stable, Potent, and Efficacious MDM2 Inhibitor

Novel inhibitor of TMPRSS2, also strongly preventing SARS-CoV-2 multiplication and CPE in Calu-3 cells in a dose-dependent manner. causing strong inhibition of SARS-CoV-2 replication

Novel MDM2 antagonist, restoring p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

Novel matriptase-1/matriptase-2 (MT-1/2) inhibitor, also inhibiting TMPRSS2, proteolytic activation and multiplication of influenza A virus in Calu-3 cells

Highly Potent and Efficacious MDM2 Inhibitor

Novel inhibitor of microtubule assembly, inducung mitotic arrest and apoptosis of MM cells

Novel Potent MIF Degrader

Immunomodulator, regulating the activation of monocytes and macrophages, upregulating the secretion of pro-inflammatory cytokines such as TNF-alpha, IL-1, IL-8, nitric oxide and prostaglandins E2 and D2

Novel inhibitor of Migration-Inducting Gene 7 (MIG-7) expression, suppressing EOC cell growth and VEGFA expression

Product Description:

MAO-B inhibitor and glycine prodrug, being studied for treatment for the symptoms of Alzheimer's disease

Natural anti-tumor agent, demonstrating with tumor inhibitory efficacy comparable or even superior to the mainstay chemotherapeutics paclitaxel or fluorouracil

First-in-class inhibitor of MYC-induced nuclear antigen (MINA53) with selectivity over NO66 and other JmjC oxygenases

Inhibitor of cholecystokinin B receptors (CCK2)

Novel inhibitor of the prostate-specific membrane antigen (PSMA)

Novel inhibitor of the prostate-specific membrane antigen (PSMA)

Novel long-lasting myostatin inhibitor, significantly increasing muscle mass and hindlimb grip strength in Duchenne muscular dystrophic model mice

Novel photoactivatable allosteric ligand for the M1 muscarinic acetylcholine receptor

Novel selective positive allosteric modulator (PAM) at the M1 muscarinic acetylcholine receptor

Novel thapsigargin-based PSMA-activated prodrug, inhibiting the sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump protein

Novel specific and efficient inhibitor of miR-21 expression, inducing a 485% increase in the luciferase reporter signal at 10 μM

Novel inhibitor of microRNA-21 (miR-21)

Novel Miro1 degrader, rescuing dopaminergic neurodegeneration and promoting Miro1 degradation in Parkinson’s Disease fibroblasts

Novel degrader of Miro1 (mitochondrial Rho GTPase 1), reducing Miro1 levels in fibroblasts and stress-induced degeneration of dopaminergic neurons derived from Parkinson's disease (PD) patients, as well as age-dependent neuronal loss and prolongs lifespan

Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor

The first small molecule inhibitor of Mitf-E-box DNA binding with depigmenting activity

Sensitive and specific Raman probe for live cell imaging of mitochondria

Fluorescent probe for measuring the activity levels of erasers of S-palmitoylation, acyl-protein thioesterases (APTs), within mitochondria of live cells

Radiation Mitigator, reducing lipid hydroperoxides and preventing apoptotic cell death

Novel mitochondrial-targeted pan-APT inhibitor

Novel potent antiproliferative mitochondria-targeted OXPHOS inhibitor (IC50=38 nM) in MiaPaCa-2 cells, being more effective than other inhibitors of OXPHOS in MiaPaCa-2 and U87MG cells

Novel selective fluorescent H2O2 probe, tracking the mitochondria of live biological specimens and responds to local fluxes of hydrogen peroxide (H2O2) by a turn-on fluorescence enhancement

Antineoplastic DNA alkylating agent

Specific inhibitor of the cellular inosine-5-monophosphate dehydrogenase (IMPDH); Immunosuppressive agent

Potent and selective PDE4 inhibitor

Novel potent, orally active and selective agonist of the melanocortin receptor 4 (MC4R)

The class III antiarrhythmic agent, blocking HERG, a human cardiac delayed rectifier K+ channel

Novel Dipeptidyl peptidase IV (DPP-4) inhibitor, improving neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression

Potent and Selective 5-Lipoxygenase Inhibitor

Selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor

Selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor

Novel Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure

Novel renin inhibitor

Potent TRPV1 antagonist